Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Privosegtor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Privosegtor | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Privosegtor | DRUG | Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days |
| Methylprednisolone | DRUG | Methylprednisolone 1 g/day IV for 5 treatment days |
| Placebo | OTHER | 0.9% sodium chloride (NaCl) solution IV for 5 treatment days |
Key Inclusion Criteria: * Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. * Onset of visual loss symptoms in the previous 12 days before first administration of study treatment. Key Exclusion Criteria: \- Have a hist...
Privosegtor is an investigational small molecule developed by Oculis Holding AG for the treatment of optic neuritis, an inflammatory condition affecting the optic nerve. It is currently in Phase 3 clinical development and has received Breakthrough Therapy, Orphan Drug, and Priority Review designations from the FDA.
Privosegtor is being developed for optic neuritis, a neurological condition involving inflammation of the optic nerve. It is an investigational therapy in Phase 3 testing and is not yet approved for commercial use. The FDA has granted it Breakthrough Therapy, Orphan Drug, and Priority Review designations for this indication.
Privosegtor targets SGK2, also known as serum and glucocorticoid-regulated kinase 2. It is a small molecule designed to modulate this target as a potential treatment for optic neuritis. Targeting SGK2 represents a specific molecular approach in the neurology therapeutic area.
Privosegtor is being developed by Oculis Holding AG, a biopharmaceutical company traded under the ticker OCS. Oculis is advancing the drug through Phase 3 clinical development for optic neuritis, with the FDA having granted Breakthrough Therapy, Orphan Drug, and Priority Review designations.
Privosegtor is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 3 trial is currently recruiting participants, and the program has received Breakthrough Therapy, Orphan Drug, and Priority Review designations from the FDA.
Privosegtor is being evaluated in a Phase 3 clinical trial, NCT07623668, titled Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research. The trial is recruiting, with an estimated enrollment of 210 participants, and is a randomized, double-blind, placebo-controlled study conducted in the United States.